Gefapixant

CHEMBL3716057 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

353.4 g/mol

LogP

0.7

Phase

4

This oral medication blocks P2X3 receptors on sensory nerves in the airways to reduce the hypersensitivity that causes chronic, unexplained cough. It is the first medication developed specifically to target this receptor pathway for the treatment of refractory chronic cough.

Masse moléculaire

353,4000 g/mol

LogP

0,70

TPSA

165,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Endometriosis Asthma

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O

InChI

InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)

Molecular Formula

C14H19N5O4S

HBD / HBA

3 / 9

Liaisons Rotatives

5

Atomes Lourds

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This oral medication blocks P2X3 receptors on sensory nerves in the airways to reduce the hypersensitivity that causes chronic, unexplained cough. It is the first medication developed specifically to target this receptor pathway for the treatment of refractory chronic cough.

Yes, Gefapixant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3716057. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 24764487. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Gefapixant sur PillFYI

Structure

Données Clés

Formule: C14H19N5O4S

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.